Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

Table 1 Comparison of Selected Drugs in Terms of a Response

Agent	Splenomegaly¹	Anemia²	Symptoms³	References
IMiDs
Thalidomide	19 %	43 %	NS	[15]
(Celgene Corp., Summit, NJ, USA)	8 %	22 %	NR	[16]
Lenalidomide	10 %	19 %	NR	[48]
(Celgene Corp., Summit, NJ, USA)	42 %	30 %	NR	[18]
Pomalidomide	0	≤40 %	NR	[21]
(Celgene Corp., Summit, NJ, USA)	11 %	37 %	NR	[22]
(Celgene Corp., Summit, NJ, USA)	0	17 %	NR	[23]
JAK Inhibitors
Ruxolitinib (INCB018424)	44 %	14 %	52–82 %	[42]
(Incyte Corporation, Wilmington, DE, USA—US rights; Novartis AG, Basel, Switzerland—ex-US rights)	42 %⁴	NR	46 %⁵	[43]
	32 %⁵	NR	NR	[44]
SAR302503 (TG101348) (Sanofi, Paris, France)	39 %	0	25–89 %	[47]
CYT387 (Cytopia/YM Biosciences, Mississauga, Ontario, Canada)	45	50 %	NR	[49]
Pacritinib (SB1518) (S*Bio Pte Ltd, Singapore)	44 %	<1 %	NR	[50]
Lestaurtinib (CEP-701) (Cephalon, Frazer, PA, USA)	18 %	1 %	NR	[51]
mTOR Inhibitor
Everolimus (RAD001) (Novartis AG, Basel, Switzerland)	17 %	<1 %	69 %⁵	[52]

IMiDs = immunomodulatory drugs; NR = not reported; NS = not significant.
¹Percentage of patients achieving ≥50 % reduction in spleen size, unless otherwise specified.
²Percentage of patients achieving a ≥2 g/dL increase in Hb, unless otherwise specified.
³Percentage of patients achieving complete resolution of symptoms.
⁴Percentage of patients achieving ≥35 % reduction in spleen volume.
⁵Percentage of patients achieving ≥50 % reduction in total symptom score on the Myelofibrosis Symptom Assessment Form.

ISSN: 1756-8722